The arrival of non-vitamin K antag­onist oral anticoagulants (NOACs) on the Australian market triggered a massive spend on doctors’ education by drug manufacturers, researchers say.

The agents consumed more than a quarter of individual companies’ educational event funding between 2011 and 2015, data shows.